Introduction: Efficacy of tildrakizumab (TIL), a high-affinity, humanized, IgG1/κ monoclonal antibody against IL-23p19, has been evaluated for chronic plaque psoriasis (Pso) in 2 phase 3 randomized controlled trials. The objective of this analysis was to determine predictors of response to TIL treatment in the 2 trials.
Παρασκευή 10 Αυγούστου 2018
Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Photochemistry and Photobiology, Volume 0, Issue ja , -Not available-.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.